Replies to post #181672 on Biotech Values

[caravon]

Since CLVS wants to do it alone for a while, they need money. So, financing is just a matter of time.

Furthermore, for money changers, CLVS is a "dead" stock since no news for another 3 months. Take into account that there is very little clinical data available from CLVS CO-1686 or AZN AZD-9291 in EGFR T790M+ NSCLC, consequently, there are many risks and plenty speculations.

PS
Just look how much money money-changers made today in GILD.